ReviewFrontiers in cellular and infection microbiology2025
Progress of single-cell sequencing technology in immunotherapy for tuberculosis.
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the 2024 World Health Organization (WHO)Global Tuberculosis (TB)Report, tuberculosis remains the leading cause of death from a single infectious agent, with 10.8 million new cases and 1.25 million deaths in 2023. Early and standardized treatment upon definitive diagnosis holds significant importance for the prevention and prognosis of pulmonary tuberculosis patients. However, the number of drug-resistant tuberculosis(DR-TB) cases is increasing, while the interventions for tuberculosis are becoming increasingly limited. There is an urgent need to develop new rapid diagnostic methods and effective treatment drugs. Recent advances in tuberculosis immunotherapy have shown promising results. Novel therapeutic vaccines like M72/AS01E demonstrate 54% efficacy in preventing pulmonary TB, while host-directed therapies including nano-based drug delivery systems offer enhanced treatment outcomes. The immune system plays a vital role in the development and regulation of tuberculosis. Single-cell sequencing(SCS) technology enables comprehensive analysis of immune cells at the single-cell level, revealing the functions, states, distributions, and communication behaviors among immune cell subpopulations. These insights contribute to understanding the pathogenesis and discovering new diagnostic markers and therapeutic targets in tuberculosis. This review provides a critical overview of the immunological mechanisms underlying tuberculosis, immunotherapy for tuberculosis, and single-cell sequencing technology, with specific focus on key findings from recent studies and their clinical implications. It primarily focuses on discussing the research progress of single-cell sequencing technology in the context of tuberculosis immunotherapy and identifies current challenges and future research priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.